Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Active ingredients: methylprednisolone
What it is used for
INDICATIONS AS AT 17 NOVEMBER 2004: A.For Intramuscular Administration. When oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-NISOLONE is indicated as follows: 1. Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone acetate is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone acetate is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used). Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Congenital adrenal hyperplasia. Hypercalcaemia associated with cancer. Non-suppurative thyroiditis. 2. Rheumatic Disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Epicondylitis. Synovitis of osteoarthritis. Acute non-specific tenosynovitis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. Acute and subacute bursitis. 3. Collagen Diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. Systemic dermatomyositis (polymyositis). 4. Dermatological Diseases. Pemphigus. Bullous Contact dermatitis" href="/contact-dermatitis" target="_blank">dermatitis herpetiformis. Severe erythema multiforme (Stevens-Johnson Syndrome). Severe seborrhoeic dermatitis. Exfoliative dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Drug hypersensitivity reactions. Contact dermatitis.Urticarial transfusion reactions. Atopic dermatitis. Acute non-infectious laryngeal oedema (adrenaline is the drug of first choice). Serum sickness. Seasonal or perennial allergic rhinitis. 6. Ophthalmic Diseases. Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Sympathetic ophthalmia. Iritis, iridocyclitis. Anterior segment inflammation. Chorioretinitis. Allergic conjunctivitis. Diffuse posterior uveitis. Allergic corneal marginal ulcers. Optic neuritis. Keratitis. 7. Gastrointestinal Diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases.Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculous chemotherapy. Aspiration pneumonitis. Loeffler's Syndrome not manageable by other means. 9. Haematological Disorders. Acquired (autoimmune) haemolytic anaemia. Erythroblastopenia (RBC anaemia). Secondary thrombocytopenia in adults. Congenital (erythroid) hypoplastic anaemia. 10. Neoplastic Diseases. For palliative management of: Leukaemias and lymphomas in adults. Acute leukaemia in childhood. 11. Oedematous States. To induce diuresis or remission of proteinuria in the nephrotic syndrome without uraemia of the idiopathic type or that due to lupus erythematosus. 12. Nervous System. Acute exacerbations of multiple sclerosis. 13. Miscellaneous. Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy. Trichinosis with neurological or myocardial involvement. B. For Intra-Articular Or Soft Tissue Administration DEPO-NISOLONE is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Epicondylitis. Rheumatoid arthritis. Acute non-specific tenosynovitis. Acute and subacute bursitis. Post-traumatic osteoarthritis. Acute gouty arthritis. C. For Intralesional Administration. DEPO-NISOLONE is indicated for intralesional use in the following conditions: Keloids.Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. Localised hypertrophic, infiltrated inflammatory lesions of Licen Planus, psoriatic plaques, Granuloma Annulare and Lichen Simplex Chronicus (neurodermatitis). DEPO-NISOLONE may also be useful in cystic tumours of an aponeurosis or tendon (ganglia).
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Intraarticular
- Store below 30 degrees Celsius
- Do not Freeze
- Shelf lifetime is 3 Years.
Always read the label. If symptoms persist see your healthcare professional.
White to off white suspension when mixed
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December 1, 2018. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient methylprednisolone
This medicine is generally considered safe during pregnancy if taken as directed. During pregnancy, you should discuss your medicine use with your doctor or pharmacist.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems